https://www.regeneronmedical.com/content/a1bPr000004sX9ZIAU/linvoseltamab-versus-realworld-international-myeloma-working-group-standardof2026-04-17T11:13:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sX9aIAE/effectiveness-of-linvoseltamab-versus-realworld-standardofcare-in-tripleclas2026-04-17T11:13:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEPIA2/clinical-and-patientreported-outcomes-in-cpost-phase-3-trial-of-adjuvant-cemi2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEQIA2/cemiplimbrwlc-survivorship-and-epidemiology-case-a-prospective-noninterven2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXERIA2/a-multicentre-openlabel-phase-2-study-of-intratumoural-tolllike-receptor-9-a2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXESIA2/comparative-economic-analysis-of-bcell-maturation-antigen-bcmatargeted-bispe2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXETIA2/budget-impact-analysis-of-linvoseltamab-for-the-treatment-of-relapsedrefractory2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEVIA2/time-to-treatment-initiation-and-vision-outcomes-in-treatmentna%C3%AFve-eyes-with-ma2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEWIA2/spectrum-latest-clinical-data-from-the-first-global-realworld-study-of-afliber2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEXIA2/spectrum-latest-clinical-data-from-the-first-global-realworld-study-of-afliber2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEYIA2/spectrum-early-realworld-treatment-patterns-with-aflibercept-8-mg-in-patients2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEZIA2/spectrum-uk-cohort-analysis-early-realworld-outcomes-with-aflibercept-8-mg-in2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEaIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-neovascular-agerelated-macular2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEbIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-namd-or-dme-analysis-of-the-med2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEcIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-diabetic-macular-edema-dme-an2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEdIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-namd-or-dme-analysis-of-the-k2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEeIAM/pulsar-extension-week-156-outcomes-with-aflibercept-8-mg-in-patients-with-namd2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEfIAM/pulsar-extension-sustained-clinical-outcomes-with-reduced-treatment-burden-afte2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEgIAM/pulsar-extension-safety-analysis-of-aflibercept-8-mg-through-156-weeks-in-patie2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEhIAM/pulsar-extension-156week-retinal-fluid-and-ped-outcomes-in-patients-with-namd2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEiIAM/pigment-epithelial-detachment-outcomes-with-aflibercept-8-mg-versus-aflibercept2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEjIAM/intraocular-pressure-outcomes-with-aflibercept-8-mg-and-2-mg-in-patients-with-di2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEkIAM/impact-of-baseline-bl-central-retinal-thickness-crt-on-visual-and-anatomic-o2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXElIAM/impact-of-baseline-bl-bestcorrected-visual-acuity-on-visual-and-anatomic-outc2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEmIAM/highprecision-measurement-of-retinal-sensitivity-by-means-of-10session-athome2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEnIAM/early-global-analysis-of-intraocular-pressure-changes-in-patients-with-namd-and2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEoIAM/early-clinical-results-in-spain-of-the-global-realworld-spectrum-study-of-aflib2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEpIAM/clinical-outcomes-of-aflibercept-8-mg-for-retinal-vein-occlusion-in-subgroups-de2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEqIAM/budget-impact-analysis-of-patients-with-namd-or-dme-who-may-require-monthly-dosi2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXErIAM/aflibercept-8-mg-in-macular-edema-following-retinal-vein-occlusion-mefrvo-642026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEsIAM/a-novel-systemic-approach-to-geographic-atrophy-with-pozelimab-in-combination-wi2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEtIAM/spectrum-early-realworld-treatment-patterns-with-aflibercept-8-mg-in-patients2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tP7tIAE/a1bpr000002tp7t2026-04-17T11:18:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sk0LIAQ/safety-and-efficacy-of-dboto-gene-therapy-in-children-with-profound-deafness-du2026-04-17T15:41:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004TN29IAG/auditory-content-otoferlinrelated-hearing-loss-mini-deck2026-04-17T15:51:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEUIA2/rapid-and-sustained-efficacy-of-subcutaneously-administered-cemdisiran-without-c2026-04-17T17:01:01.000Zhttps://www.regeneronmedical.com/content/a1bPr000004t5zFIAQ/proclinical-presentation-diagnosis-of-rvo-mini-slide-deck2026-04-18T01:00:42.000Z